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This dissertation is presented in an article format. The findings of the study are presented in 
chapter 3, in manuscript format as required by the regulations of the University of KwaZulu-
Natal. One manuscript will be submitted for publication in the South African Medical Journal 
(SAMJ). The reference list is cited according to the instructions for authors as required by the 
SAMJ. A complete reference list is included at the end of every chapter and according to the 
reference style of the University of KwaZulu-Natal.  
 
The dissertation consists of four chapters as follows: 
 Chapter 1: provides an introduction to the study as well as the aims, objectives and a 
brief overview of the methodology.  
 Chapter 2: highlights the literature review of adverse drug reactions relating to 
incidence and prevalence, HIV/AIDs, patient adherence, monitoring, cost implications 
and pharmacovigilance in South Africa.  
 Chapter 3: consists of the results, discussion and conclusion written in a manuscript 
format.  
 Chapter 4: provides the general conclusions, recommendations, limitations and 



















Background and Aim 
South Africa has one of the highest prevalence’s of human immunodeficiency virus (HIV) and 
acquired immunodeficiency syndrome (AIDS) infected people in the world. HIV/AIDS patients 
face countless challenges, one of which is the risk of adverse drug reactions. This study aimed 
to describe the ADRs reported in South Africa with reference to the type of ADR, ARVs 
implicated, seriousness of the ADR and patient demographics associated with specific ADRs.  
  
Methods  
A retrospective quantitative study was carried out using ADR reports which were submitted to 
the National Department of Health during 01 January 2010 – 31 December 2014. Data, obtained 
electronically in the form of case study reports, was transcribed onto Microsoft Excel (version 
10) and analysed using SPSS (version 19). A descriptive and inferential analysis was carried 




A total of 2489 reports were analysed, of which the majority of ADRs reported were 
experienced by female patients (n=1511, 66.7%) as opposed to male patients (n=755, 33.3%). 
This study found evidence of a high degree of adverse drug reactions among patients on first-
line ART with stavudine (n=1256, 50.46%), efavirenz (n=572, 22.98%), zidovudine (n=209, 
8.40%), tenofovir (n=203, 8.16%) nevirapine (n=153, 6.15%) based regimens. The 10 most 
common ADRs reported with the use of ARVs were peripheral neuropathy (n=472, 19%), 
lipodystrophy (n=471, 18.9%), serious skin reactions (n=266, 10.7%), gynaecomastia (n=219, 
8.8%), renal failure (n=140, 5.6%), dizziness (n=133, 5.3%), hyperlactatemia (n=118, 4.7%), 
psychosis/hallucinations (n=47, 1.9%), sleep disturbances (n=44, 1.8%) and vomiting (n=44, 
1.8%). Peripheral neuropathy and lipodystrophy were the most common ADRs amongst the 
female patients who received stavudine treatment in the 30-44 year age group.  
 
Discussion and Conclusion  
Female patients were more likely to experience peripheral neuropathy, lipodystrophy, skin rash, 
anaemia and hyperlactatemia, while male patients were more prone to experience 
gynaecomastia and peripheral neuropathy. In addition, patients aged 30-44 years old reported 
iv 
 
the most ADRs. Most reactions were caused due to the use of stavudine, efavirenz, zidovudine, 
nevirapine and tenofovir in the population groups identified in this study.  
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During the course of pharmacological therapy certain drugs can produce effects other than those 
that are desired or likely.[1] These effects, which are known as adverse drug reactions (ADRs) 
raise concerns to both, the clinician and patient, adding to the cost of medical treatment, and 
increase in morbidity and mortality.[1, 2] ADRs are between the fourth and sixth leading cause of 
death globally.[1]  The World Health Organization (WHO) defines pharmacovigilance (PV) as 
“the science and activities relating to the detection, assessment, understanding, and prevention 
of adverse effects or any other possible drug-related problems.”[3] This study aims to describe 
the ADRs reported in South Africa (SA) amongst patients using antiretrovirals (ARVs), with 
reference to the types and seriousness of ADRs reported, patient demographics associated with 
specific ADRs, and the types of ARVs mostly involved in ADRs.  
 
1.1 Background and rationale for this study 
 
ADRs have been creating headlines over the last 50 years and are one of the foremost causes of 
morbidity and mortality in healthcare.[4] It is almost axiomatic that all drugs carry the potential 
to produce undesirable effects, in addition to the desired ones.[4,5] In the last few decades, our 
country has seen a vast growth in the availability and consumption of medicines.[6] Whilst most 
patients gain far more benefit than harm, a large proportion of patients experience the 
undesirable effects from the use of medicines which occurs at recommended doses and 
frequencies.[7] For some, these adverse effects are severe enough to require hospitalization or 
may even result in death.[7] ADRs have shown to diminish a person’s quality of life, leading to 
increased physician visits and hospitalizations.[8] 
 
The WHO defines an ADR as “any response to a drug which is noxious and unintended and 
which occurs at doses used in man for the prophylaxis, diagnosis or therapy of disease, or for 
the modification of physiological function”.[3] 
 
ADRs refer to the unwanted or dangerous effects that a drug may possess.[9] The incidence and 
severity of ADRs are influenced by patient characteristics such as age, gender, body weight, 
coexisting diseases, ethnicity, genetic or geographic factors and by drug factors such as the type 





ADRs can be grouped into categories/types such as those specified on the ADR reporting form 
(Annexure 4) which is used in South Africa. ADRs can be grouped as one of the following; 
haematological (e.g. neutropaenia, anaemia), dermatological (e.g. skin reactions), central 
nervous system (e.g. depression, epilepsy), metabolic (e.g. acidosis, diabetes, hyperkalaemia), 
reproductive (e.g. gynaecomastia, sexual dysfunction), gastrointestinal (e.g. nausea, vomiting, 
diarrhoea) bone disorders (e.g. osteopenia, osteoporosis), cardiovascular (e.g. arrhythmia, 
coronary angioblasty), hepatic (e.g. hepatitis, pancreatitis), neurological (e.g. peripheral 
neuropathy), renal (e.g. nephrotoxicity, renal failure) or other events .[3] The seriousness of 
ADRs can vary and may result in persistent or significant disability/incapacity, hospitalization, 
a medically important or life-threatening condition, or even death.[10]  They commonly occur as 
a result of pharmacokinetic interactions (e.g. drug absorption, drug excretion, enzyme induction, 
enzyme inhibition) or pharmacodynamic interactions (drug-drug interactions, e.g. synergistic 
interactions, opposing interactions).[11] 
 
In addition, allergic reactions and combinations of incompatible medications can also lead to the 
development of ADRs.[11,12] These occur due to the inability to know everything about a drug 
and its potential effects prior to it being marketed.[13] Also, interactions between multiple 
medications are often not determined in the pre-market phase of drug testing.[13] However, some 
ADRs are caused, or perpetuated, by human practices.[13] These comprise patient non-
compliance with medication regimens as well as prescription and dispensing errors. Even 
though these complications seem inexorable, there are ways to curtail their occurrence and 
diminish their prevalence, such as focusing attention and study on particular groups of people 
who suffer more frequently from drug allergies and medication interactions.[11,13] 
 
1.2 Research questions  
 
This study focused on the following research questions: 
1.2.1 What are the different types of ADRs reported in South Africa and associated with the 
use of ARVs?  
1.2.2 Which ARVs result most often in ADRs?  
1.2.3 What is the seriousness of the reported ADRs? 








1.3 Aims and objectives for this study 
 
The aim of this study was to describe the ADRs reported in South Africa with reference to the 
types and seriousness of ADRs reported, patient demographics, and ARVs involved. To achieve 
this, the following specific objectives were outlined:  
 
1.3.1 To identify the types of ADRs that have been reported in South Africa. 
1.3.2 To identify the ARVs most involved in the reported ADRs mentioned above. 
1.3.3 To determine the seriousness of reported ADRs based on the patient outcome. 
1.3.4 To examine the patient demographics of the reported ADRs in relation to the type of 
ADR and ARVs implicated. 
 
1.4 Significance of the study 
 
In the United Kingdom (UK) and United States of America (USA), studies conducted to assess 
morbidity and mortality associated with ADRs have mainly been restricted to hospitalized 
patients, the occurrence of ADRs among in-patients, and the misuse of drugs that lead to the 
development of ADRs.[11,13] Similarly, studies conducted in some parts of SA, have also been 
restricted to in-patients and patients that are admitted to hospitals for ADRs.[14] Furthermore, 
studies to evaluate the most prevalent types of ADRs reported in SA and most common ARVs 
involved, have either been restricted to certain provinces or specified over a much shorter time 
frame.[15]  
 
In hope to endorse the rational and cost effective use of medicines, to ensure patient safety, and 
to minimize morbidity and mortality, studies have been conducted in different provinces of 
South Africa to help describe ADRs reported with reference to highly active antiretroviral 
treatment (HAART) patients, medication regimens, and reporting systems.[10]  
 
No studies have been conducted to quantify the types of ADRs experienced most frequently by 
specific patient population groups in South Africa. In addition, this study will add to the 
growing literature as it focuses on ADR reports from 01 January 2010 up to and including 31 
December 2014. It will also highlight the types of ADRs reported, patient demographics and 
ARVs involved. Although many drugs have been tested, tried and used in developed countries, 




incidence and severity of ADRs may differ because of local environmental and genetic 
influences.[16] Further, scant data on the global burden of ADRs is available.[17] Thus, the 
surveillance of medicine-related ADRs is a vital way to optimize patient safety.  
 
The knowledge of the most prevalent ADRs, ARVs involved, and population groups most at 
risk of developing ADRs can help pave the way to ameliorate the incidence of ADRs 
experienced by specific populations in South Africa.[18] This can assist with reinforcing the 
goals set out by the National Department of Health (NDoH) to help strengthen strategies to 
maximize patient safety, allow for easier patient monitoring, ensure the rational use of 
medicines, and reduce healthcare costs. Considering the impact ADRs have on a patient’s 
quality of life, and morbidity and mortality rates in South Africa, a major stepping stone to 
achieving ways to detect or prevent ADRs before they proliferate would be to know which 
population groups are most susceptible to these harmful reactions and which ARVs are most 
likely to cause them.  
 
1.5 Research methodology  
 
1.5.1 Study design 
A retrospective quantitative study of case reports was carried out on ADRs reported to the South 
African National Department of Health between 01 January 2010 and 31 December 2014. 
 
1.5.2 Data source  
All case reports submitted over the stipulated time frame (01 January 2010 – 31 December 
2014), to the National Department of Health (South Africa), were included in the study. Data 
was received electronically in the form of case reports as a Microsoft Excel document from the 
National Department of Health Pharmacovigilance centre. The inclusion criteria encompassed 
case reports that had an ADR reported with the use of ARVs and were submitted during 01 
January 2010 – 31 December 2014. The exclusion criteria consisted of case reports that; were 
incomplete and had no ADR indicated which could be due to incomplete data 
capturing/reporting, as well as ADRs reported for medicines other than ARVs (anti-tuberculosis 
and anti-hypertensive medicines), ADR forms submitted for treatment failure, and reports 







1.5.3 Data analysis 
A total of 4286 ADR reports were received, of which 1797 were excluded from the study as per 
the inclusion and exclusion criteria. Therefore, the sample size (N) accumulated to 2489 reports 
for analysis. The data was in the form of case study reports which included the type of ADR 
reported (e.g. dermatological, metabolic, etc.), the patient outcome (resulting in death, life 
threatening, etc.), the ARVs that were involved, the patients’ age, gender, weight, underlying 
disease, as well as their ARV regimen and possible causative agent. Data was coded using 
numbers and thereafter transcribed onto Microsoft Excel (version 2010) using a data extraction 
sheet and analysed using SPSS (version 19).  
 
1.5.4 Data Management 
The extraction sheet will be stored on a password protected computer in the supervisor’s office 
and destroyed after 5 years. The original data sets that were obtained electronically from the 
NDoH PV centre will be permanently deleted.  
 
1.5.5   Ethical approval  
Full ethical approval for the study was obtained from the Humanities and Social Sciences 
Research Ethics Committee of the University of KwaZulu-Natal (HSS/0916/015M) 27 August 
2015 – (Annexure 1), and permission to use the data sets was obtained from  the South African 
National Department of Health – 24 March 2015 (Annexure 2). No patient hospital numbers, 
names/surnames/initials/ or date of birth/identification numbers were reported in the data sets, 
hence, patient confidentiality was maintained at all times.  
 
1.6 Chapter summary   
 
This chapter provided a background and rationale to the study, explaining ADRs. It also 
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South Africa is home to approximately 52 million people.[1] With more than 50% of the 
population living in poverty and many unemployed, government hospitals are over burdened in 
efforts to provide essential healthcare.[1,2] The incidence of ADRs amongst this population 
increases exponentially.[1,2] 
 
ADRs impact profoundly on our healthcare system, contributing significantly to patient 
morbidity, mortality, hospital admissions, and healthcare costs.[2,3] In attempt to closely monitor 
and help reduce the incidence of ADRs in the country, the National Department of Health has 
employed a Pharmacy and Therapeutics Pharmacovigilance committee to advise the Department 
of Health on issues relating to ADRs in order to promote the rational and cost-effective use of 
drugs in accordance with standard treatment guidelines.[2] The objectives of this committee are 
to promote the safety of the patient, endorse the rational and cost effective use of drugs, inform 
healthcare institutions of policy and guideline changes, promote awareness of ADRs and the 
need to report all suspected ADRs.[2]  
 
Developing awareness of the potential risks of medicines, while also understanding the extent of 
their benefits, is critical to addressing the problem of drug-induced diseases.[4] Failing to 
maintain constant vigilance when using medicines in patients can have devastating and even 
fatal consequences. This vigilance is required throughout the patient-practitioner relationship, 
i.e. when patients are being asked about their medicine use and medical history, when 
diagnosing a disease condition, and when prescribing, monitoring, and reassessing 
management.[4]  
 
When a new medicine is released into the market, there is still a substantial amount that is 
unknown about the safety of the medicinal product.[5,6] The patients that are studied in the pre-
marketing clinical trials of new medicines are usually limited to a small number and are studied 
for a short period of time.[6] Hence, only the more common ADRs are detected during the 
clinical trials. Information about rare but serious ADRs, drug interactions, chronic toxicity, and 
risks in special patient groups (e.g. paediatric groups, geriatric groups, males, females, certain 





It seems clear from the presented evidence that ADRs have become a major global health 
problem that needs to be addressed at all levels of healthcare.[7] The lack of awareness of size 
and severity of the problem are partially to blame for this silent epidemic.[4] Furthermore, a large 
proportion of these ADRs can be prevented through more judicious medicine use.[7] Knowledge 
of the most common ADRs and population groups that are prone to experiencing ADRs can 
help reinforce the goals set out by the National Department of Health to help strengthen 
strategies to maximize patient safety, ensure the  rational use of medicines, and reduce 
healthcare costs.[3]  
 
2.2 Adverse drug reactions and HIV/AIDS  
 
South Africa has one of the highest prevalence’s of HIV-infected people in the world and is 
home to 17.9% of the reported 36.9 million people living with HIV/AIDS worldwide.[8] 
According to reports from the joint-United Nations programme on HIV/AIDS (UNAIDs) and 
Statistics South Africa, Sub-Saharan Africa is the region worst affected by the HIV and AIDS 
epidemic.[8] South Africa has the highest prevalence of HIV/AIDS compared to any other 
country in the world with 6.1 million people living with HIV, and 240,000 HIV related deaths 
recorded in 2012 alone.[9]  HIV prevalence varies markedly between provinces in SA with a 
soaring 40% HIV prevalence in KwaZulu-Natal (KZN) as compared to 18% in the Northern 
Cape and Western Cape.[10] Statistics revealed that the annual number of deaths in South Africa 
from HIV/AIDS rose by a massive 93% between 1997 and 2006, and then decreased by 11% 
between 2006 and 2010.[10]  
 
South Africa has the largest ARV treatment rollout programme in the world, which achieved a 
75% increase in antiretroviral therapy (ART) services between 2009 and 2011.[10] By the end of 
October 2012, over two million people were receiving ART, surpassing SA's universal target 
(80%) in accordance with the 2010 WHO treatment guidelines (offering ART to people with a 
CD4 count less than 350 cells/mm³).[10]  
 
The Human Immunodeficiency Virus has transformed from life-threatening to a chronic 
condition for the majority of patients due to the universal use and ease of accessibility of ART 
amid HIV-infected patients’.[11] ARV treatment works by providing suppression of a patients 
viral load and restoring their immune system. Nearly 6.6 million HIV/AIDS related deaths 




mortality rates of HIV-infected individuals, the South African National Department of Health, 
together with the South African government and guidelines from the WHO, enforced and 
encouraged physicians to initiate HIV-infected patients on HAART combination therapy based 
on the patients’ clinical staging as per WHO, viral load and CD4 count. HAART consists of 1st 
and 2nd line regimens.[11]  
 
Antiretroviral therapy consists of three ARVs that are capable of suppressing HIV replication 
when used in combination. The usual ARV regimen contains two nucleoside reverse 
transcriptase inhibitors (NRTIs) together with either a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) or a protease inhibitor (PI). Orally administered NRTIs include tenofovir 
(TDF), lamivudine (3TC), abacavir (ABC), emtricitabine (FTC), stavudine (d4T), didanosine 
(DDI) and zidovudine (AZT). NNRTIs include efavirenz (EFV) and nevirapine (NVP), while 
protease inhibitors include lopinavir/ritonavir (LPV/r) and atazanavir (ATV).[12] The following 
ARV regimens were available during the study period. First line regimens comprised of 
d4T/3TC/EFV, d4T/3TC/NVP, TDF/3TC/EFV, TDF/3TC/NVP, FTC/TDF/EFV, 
FTC/TDF/NVP, AZT/3TC/EFV, AZT/3TC/NVP, ABC/3TC/EFV, ABC/3TC/NVP. Second line 
regimens consisted of TDF/3TC and LPV/r, AZT/3TC and LPV/r or ABC/3TC and LPV/r. 
 
Research has shown that ART increases the emotional and physical quality of life for people 
living with HIV/AIDS.[13,14] Conversely, even with ART, HIV/AIDS patients face countless 
challenges. These patients remain at risk of ADRs and other complications, both short and long 
term.[15]   
 
Patients that are on ART are at increased risk of experiencing ADRs due to the effect of the 
disease, as well as the complex drug regimens that they take.[15] Numerous patients have been 
reported to have toxicity concerns and on many occasions they are indisposed to start or adhere 
to treatment.[16] 
 
A retrospective review on ADRs reported in Mpumalanga (South Africa) from 2011 to 2013 
depicted that a total of 1756 HIV-infected patients experienced an ADR whilst on ART.[17] 
During May 2007 – May 2008, 3534 patients experienced ADRs in KwaZulu-Natal as a result 






 Thus, ADRs may rigorously jeopardize the confidence in the safety of ART, thereby altering 
patient adherence, increasing the risk for the emergence of drug resistance, and reducing 
treatment efficacy.[18]  
 
2.2.1 Adverse drug reactions commonly associated with antiretrovirals   
The risk of ADRs arises due to the effect of disease on the immune system and the safety 
profiles of the multifaceted  ARVs.[16] There is a range of ADRs associated to ART that have 
been recognized, and may be short to long term and/or mild to severe, depending on the 
environment.[19] ADRs in developing countries may diverge from those in developed countries 
because of high prevalence of conditions such as tuberculosis, poverty, malnutrition and 
patients presenting with an advanced stage of the disease.[20,21] 
 
A descriptive analysis conducted amongst HIV-infected patients receiving ART between 
January 2011 and December 2011 in Nigeria revealed a total of 1679 ADRs reported. Of these, 
63.2% occurred in patients on zidovudine-based regimens, 8.2% due to stavudine and 19.3% 
due to tenofovir.[22] The most common ADRs included peripheral neuropathy, skin rash, 
dizziness and pruritis. Peripheral neuropathy was mostly associated with stavudine and the 
tenofovir/efavirenz regimen, and anaemia with the zidovudine/lamivudine/nevirapine 
regimen.[22] 
 
An assessment of ADRs among HIV-infected individuals receiving ARVs in South Africa 
focused on 590 patients enrolled in the Medunsa National ARV Pharmacovigilance Surveillance 
System from February 2007 till July 2011.[21] This study identified that 37% of patients had 
experienced at least one ADR when on the stavudine, efavirenz and lamivudine combination.  
Among patients that experienced ADRs, the majority were females (74%) in the age group of 
38 to 44 years (39%).[21] Similar to the Nigerian study, there was a high incidence of peripheral 
neuropathy (20% of all ADRs), followed by skin eruptions (15%). In addition, cough was also 
prevailing, accounting for 12% of the ADRs. Other ADRs accounting for 16% of the overall 
reports included dermatitis, oedema, acidosis and hypothyroidism.[21] 
 
ADRs experienced by patients admitted to a South African hospital based in a community with 
a high HIV/AIDS prevalence were examined through a 3-month prospective observational 
study.[16] During data collection, 665 adults were admitted to the hospital.  Among HIV-infected 






During 2011 to 2013, Mpumalanga (South Africa) reported 1756 ADRs to the National 
Department of Health.[17] The forms reported over this time frame were analysed and the 10 
most frequent ADRs experienced were lipodystrophy, lipoatrophy, peripheral neuropathy, 
weight loss, breast enlargement and/or gynaecomastia, dizziness, rashes, vomiting, fat gain, and 
headache.[17] The two most common ADRs were lipodystrophy (327 cases) and peripheral 
neuropathy (358 cases), associated mainly with stavudine-containing regimens.[17] Whilst 
peripheral neuropathy is linked to almost all the NRTIs, it can be seen that d4T is the most 
commonly suspected drug. This is in keeping with other ART studies where a similar outcome 
had been established.[20,21] This finding supports the World Health Organizations’ 
recommendation to discontinue the use of d4T-based regimens in adolescents and adult patients 
due to the associated adverse effects.[8] Other drugs implicated include efavirenz (53 cases), 
nevirapine (29 cases), lamivudine (4 cases), and zidovudine (22 cases).[17] 
 
A study conducted in KZN found that the use of stavudine and efavirenz in ARV patients 
contributed significantly to the development of gynaecomastia. In addition, stavudine caused 
peripheral neuropathy, lipodystrophy, lactic acidosis, and symptomatic hyperlactataemia. 
nevirapine and efavirenz were shown to contribute to skin reactions.[24] 
 
It is evident that peripheral neuropathy, lipodystrophy and neutropaenia are the principal ADRs 
reported globally and within some parts of Africa. Short term ADRs are an impending threat to 
successful initiation and compliance to ART. ADRs may be specific to a class of drugs. 
Efavirenz and nevirapine were known to cause skin rashes and hepatotoxicity, while zidovudine 
and stavudine were associated with peripheral neuropathy, lipodystrophy, anaemia, nausea, 
rashes, lipoatrophy and lactic acidosis.[24] 
 
2.2.2 Incidence and prevalence of adverse drug reactions  
ADRs that are caused by immune and non‐immune mechanisms are a major cause of morbidity 
and mortality worldwide.[25] ADRs are the most widespread iatrogenic illness and are the fourth 
most common cause of death.[26] 
 
During 2013, the UK reported 31073 incidents of patients suffering serious adverse reactions to 
prescribed drugs.[27] In addition, statistics showed that 1604 reported deaths were thought to be 
triggered by severe reactions to medicines.[27] A further 6050 patients went to hospital with 




to increased physician visits, hospitalizations, and even death.[3] ADRs can also result in 
increased healthcare costs which could put a strain on the over burdened healthcare system in 
South Africa.  
 
In the USA, ADR deaths are higher amid men than women and deaths due to ADRs are 
significantly more likely in persons older than 55 years.[28] Rates were also found to be varied 
by ethnicity and race and were highest amongst blacks.[28] In addition, more than 100 000 deaths 
were attributed annually to serious ADRs.[29] Epidemiologic data suggests that specific factors 
can increase the risk of ADRs, such as the infection with HIV, age, race and gender.[30] 
 
A study conducted in Sub-Saharan Africa described the contribution of ADRs to patient 
morbidity, hospitalization and mortality.[9] The findings of this study suggest that cardiovascular 
medicines and ARVs contributed the most to community-acquired ADRs, while medicines used 
for opportunistic infections (such as antiviral medicines, antibiotics and antifungals) were most 
generally implicated in hospital-acquired ADRs.[9] In hospitalized patients, the overall incidence 
of serious ADRs was 6.7% and fatal ADRs was 0.32%, making these reactions the fourth and 
sixth leading cause of death, respectively.[26]  
 
In South Africa, a study conducted in the province of Mpumalanga, the number of ADRs 
reported from 2011 to 2013 was a total of 1057.[17] Among these, 495 (28.9%) were recorded 
from males while 1057 (60.19%) were females.[17] When these reports were categorised by age 
group, it was observed that the majority of ADRs were in the age group 31 to 40 years and with 
more reports in females (65.94%) than males (26.26%).[17] 
 
A large proportion of ADRs have been shown to be preventable through improved drug 
prescribing and monitoring.[3] 
 
2.3 Pharmacovigilance in South Africa 
 
The World Health Organization defines pharmacovigilance (PV) as “the science and activities 
relating to the detection, assessment, understanding, and prevention of adverse effects or any 
other possible drug-related problems”.[32] The PV system incorporates timely and efficient 
identification, collection, assessment, and communication of medicine-related adverse 
reactions.[32] A comprehensive PV system includes both active and passive surveillance 




incorporation of PV systems and activities into all levels of the health system, from the facility 
to the national levels.[32] 
 
With augmented access to new fundamental medicines in South Africa, there is a greater need to 
promote and monitor the safety and efficacy of medicines.[12] Besides the impact of ADRs on 
morbidity and mortality and the direct cost of managing these events, ADRs also have other 
associated costs in terms of the loss of confidence in the healthcare system, patient non-
adherence to treatment which leads to the development of drug resistance and economic loss to 
the pharmaceutical industry.[33] Although it is difficult to measure these costs, it is apparent that 
they may constitute a profound impact on the resources of the healthcare system.[33] 
 
South Africa uses a spontaneous reporting system in which healthcare providers are responsible 
for reporting suspected ADRs.[18] After sufficient monitoring, laboratory tests and adherence 
counseling, an ADR report form is filled and submitted to the NDoH. This form indicates the 
patients’ data, the ADR, current ARV regimen, viral load, CD4 count, concomitant diseases and 
medicine treatment.[18] When a patient experiences an ADR, they would most likely be switched 
to another ARV regimen in which the drug in question will be substituted with another in its 
class.[18] 
 
Spontaneous reporting systems include both in-patient and out-patient reporting and can be used 
for reporting ADRs for large groups of patients.[18] In addition, other advantages are that it can 
be used for reporting all types of medicines and is relatively inexpensive.[18] However, 
underreporting seems to be the leading challenge with this system of reporting.  Spontaneous 
reporting systems are currently being used in most parts of the world, including the UK, USA 
and India.[34,35]  
 
2.3.1 Importance of adverse drug reaction monitoring  
ADR monitoring refers to the continuous periodical assessment of a patient’s medical 
condition.[36] The aim of ADR monitoring is to prevent untoward effects that could diminish a 
patient’s quality of life, lead to death and have a negative effect on patient adherence.[36] A 
patient monitoring system is a critical component of an integrated HIV care, ART and 
prevention programme.[37]  
 
An ADR monitoring system forms the backbone of clinical care, treatment and prevention.[36] 




patients; and second, it generates data used for programme monitoring and management, 
contributing to standardized indicators at the district, national and international levels.[36] 
Proper utilization of ART requires ongoing patient monitoring to assess therapeutic responses 
and to identify adverse events related to the chronic administration of these potentially toxic 
ARVs.[37] Failure to respond to a recommended ART regimen is almost always a result of 
suboptimal adherence or viral resistance.[37] Optimal adherence (i.e., taking all medication doses 
at the time intervals prescribed) to ART is important to help patients achieve and maintain 
virological suppression.[37] Adherence can vary over time and can be impacted by factors such 
as depression, emotional stress, pill-burdens and lack of support.[37]  
 
Thus, ADRs impact negatively towards a patient’s attitude regarding treatment.[24] The 
identification of patients that are at risk to developing ADRs can help medical professionals 
make better decisions regarding drug management for diverse individuals.[36] In addition, 
patients would have a much better treatment outcome and prognosis.[36] Early detection of 
ADRs through monitoring can help prevent the unnecessary cost burden associated with 
managing the effects caused by these reactions.[36]  
 
Monitoring the safety and toxicity associated with ART remains a challenge facing the public 
health sector in South Africa.[36] ADR monitoring is typically done using a spontaneous 
surveillance method.[36] However, studies conducted globally have found that spontaneous 
reporting of ADRs to be an incompetent system as it leads to underestimation of the burden due 
to ADRs.[22] Thus, more strong surveillance methods including structured surveillance PV 
systems, which monitor and assess the safety profile and the impact of ART needs to be 
ameliorated. A structured surveillance monitoring system tracks HIV infected patients who are 
on ART to assess ARV related morbidity and mortality over time.[4] South Africa, a country 
which is heavily hit by the HIV epidemic, uses a spontaneous surveillance reporting system of 
HIV patients on ART to assess ART-related adverse effects.[4] 
 
ADRs contribute substantially to patient morbidity and hospitalization in South Africa, further 
increasing the burden and cost of managing patients in an overstretched healthcare system.[3] In 
hope to prevent these dangerous reactions, knowledge of the most prevalent ADRs is greatly 
needed.[3] To date, studies describing the types, as well as the most prevalent ADRs reported in 






2.3.2 The impact of adverse drug reactions on patient adherence  
Adherence to a medication regimen is defined as the extent to which patients take their 
medications as prescribed by their healthcare providers.[38] Medication non-adherence is a 
growing concern to clinicians and healthcare systems due to escalating evidence that it is 
prevalent and associated with adverse outcomes and higher costs of care. To date, measurement 
of patient medication adherence and the use of interventions to improve adherence are rare in 
routine clinical practice.[38]  
 
Treatment adherence is generally regarded as an essential factor in achieving optimal outcomes 
across many disease states. Poor adherence to ART has the potential to impact on outcomes on 
multiple levels.[38] Poor adherence to ART is commonly associated with a less effective viral 
load suppression, which risks the immediate health of the patient, but also risks creating 
permanent treatment resistance to that particular ARV or group of ARVs.[38] This may have 
downstream effects on treatment costs as well as therapeutic options. The causes of poor 
adherence to ART are extremely diverse, and include complexity of therapeutic regimens (e.g. 
pill burden and dosing frequency), patient forgetfulness, poor health literacy, treatment side 
effects, patients with co-morbidities, poor patient-practitioner relationship, and limited access to 
ART as a result of formulary restrictions within the public sector.[33]  
 
In addition to the primary objective of reducing the risk of morbidity and mortality associated 
with ART, the secondary goal of ART is viral load suppression.[12] Numerous effective 
therapeutic agents for viral load suppression in HIV/AIDS have been developed. Their efficacy, 
however, requires that patients with HIV/AIDS be adherent to their prescribed regimens. 
Effective use of ARVs requires not only good adherence to therapy but sustained adherence 
over time if viral load suppression is to be successful.[3]  
 
The importance to medication compliance especially for HIV-infected patients cannot be 
stressed enough. Poor adherence can lead to an increase in viral load and a decrease in CD4 
counts which in turn sets the ground for the development of opportunistic infections such as; 
cryptococcal meningitis, oesophageal candidiasis, tuberculosis and many more.[37] However, 
studies throughout the world have indicated that ADRs are associated with poor patient 
compliance as patients feel less inclined, motivated and confident about their treatment and are 





Currently, a much larger group of ARV drug combinations are being used to treat patients.[9] 
The rate of ADRs amplifies exponentially after a patient is on four or more 
medications.[9] Efforts to reduce polypharmacy are important but, for many patients, the number 
of medications cannot always be reduced without doing harm.  
 
2.3.3 Adverse drug reactions and cost implications  
ADRs are an imperative public health issue that threaten the safety of drug therapy and results 
in a considerable economic burden to the healthcare system.[39] ADRs result in an increased 
number of physician visits, new treatment to treat the ADR, and possible hospitalization – all of 
which can put a strain on an overstretched healthcare system.[39]  
 
While estimates pertaining to the cost implicated by ADRs does not form part of the study’s 
objectives, it is important to keep in mind that an estimate of the cost of drug-related morbidity 
and mortality is 136 billion US dollars annually, which is more than the total cost of 
cardiovascular or diabetic care in the USA.[39] In addition, 1 out of 5 injuries or deaths per year 
to hospitalized patients may be as a result of an ADR.[35] The severity and substantial costs of 
ADRs in hospital justify investments to prevent these events. Nonetheless, merely a segment of 
ADRs induce cost increases, suggesting that preclusion efforts should focus on this limited class 
of ADRs.[39]  
 
2.4 Chapter summary  
 
This chapter comprised of a literature study based on ADRs and HIV/AIDS. This is related to 
the incidence and prevalence of these reactions, the common ADRs reported, ARVs implicated 
in these reactions, pharmacovigilance in South Africa, as well as cost implications relating to 
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This chapter described the general findings and discussion of the results of the study and is represented 
in the form of a manuscript titled “Adverse drug reactions associated with antiretroviral therapy in 
South Africa”. This manuscript will be submitted to the “South African Medical journal” (SAMJ) for 
publication. 
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Background and Aim 
South Africa has one of the highest prevalence’s of human immunodeficiency virus (HIV) and acquired 
immunodeficiency syndrome (AIDS) infected people in the world. HIV/AIDS patients face countless 
challenges, one of which is the risk of adverse drug reactions (ADRs). This study aimed to describe the 
ADRs reported in South Africa with reference to the type of ADR, ARVs implicated, seriousness of the 
ADR and patient demographics associated with specific ADRs.  
 
Methods  
A retrospective quantitative study was carried out using ADR reports which were submitted to the 
National Department of Health during 01 January 2010 – 31 December 2014. Data, obtained 
electronically in the form of case study reports, was transcribed onto Microsoft Excel (version 10) and 
analysed using SPSS (version 19). A descriptive and inferential analysis was carried out to determine 
the strength of the relationships (Pearson Chi Square test) between different variables. 
  
Results 
A total of 2489 reports were analysed, of which the majority of ADRs reported were experienced by 
female patients (n=1511, 66.7%) as opposed to male patients (n=755, 33.3%). This study found 
evidence of a high degree of adverse drug reactions among patients on first-line ART with stavudine 
(n=1256, 50.46%), efavirenz (n=572, 22.98%), zidovudine (n=209, 8.40%), tenofovir (n=203, 8.16%) 
nevirapine (n=153, 6.15%) based regimens. The 10 most common ADRs reported with the use of ARVs 
were peripheral neuropathy (n=472, 19%), lipodystrophy (n=471, 18.9%), serious skin reactions 




hyperlactatemia (n=118, 4.7%), psychosis/hallucinations (n=47, 1.9%), sleep disturbances (n=44, 1.8%) 
and vomiting (n=44, 1.8%). Peripheral neuropathy and lipodystrophy were the most common ADRs 
amongst the female patients who received stavudine treatment in the 30-44 year age group.  
 
Discussion and Conclusion  
Female patients were more likely to experience peripheral neuropathy, lipodystrophy, skin rash, 
anaemia and hyperlactatemia, while male patients were more prone to experience gynaecomastia and 
peripheral neuropathy. In addition, patients aged 30-44 years old reported the most ADRs. Most 
reactions were caused due to the use of stavudine, efavirenz, zidovudine, nevirapine and tenofovir in the 
population groups identified in this study.  
 
Keywords: Pharmacovigilance, antiretroviral therapy, human immunodeficiency virus (HIV) and 


































Background and Introduction 
 
South Africa (SA) has one of the highest prevalence of human immunodeficiency virus (HIV) and 
acquired immunodeficiency syndrome (AIDS) infected people in the world and is home to 17.9% of the 
reported 36.9 million people living with HIV/AIDS worldwide.[1] Statistics reveals that the annual 
number of deaths in South Africa from HIV/AIDS rose by a massive 93% between 1997 and 2006, and 
then decreased by 11% between 2006 and 2010.[2,3] Nearly 6.6 million HIV/AIDS related deaths 
worldwide have been prevented as a result of anti-retroviral therapy (ART). [3] In hope to improve 
morbidity and mortality rates of HIV-infected patients, the National Department of Health (NDoH), 
together with the South African government and guidelines from the World Health Organisation 
(WHO), enforced and encouraged physicians to initiate HIV-infected patients on highly active 
antiretroviral treatment (HAART) combination therapy based on the patients’ clinical staging as per 
WHO, viral load and CD4 count.[4] HAART comprised of 1st and 2nd line regimens.[4]  
 
Antiretroviral therapy consists of three ARVs that are capable of suppressing HIV replication when 
used in combination. The usual ARV regimen contains two nucleoside reverse transcriptase inhibitors 
(NRTIs) together with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease 
inhibitor (PI). Orally administered NRTIs include tenofovir (TDF), lamivudine (3TC), abacavir (ABC), 
emtricitabine (FTC), stavudine (d4T), didanosine (DDI) and zidovudine (AZT). NNRTIs include 
efavirenz (EFV) and nevirapine (NVP), while protease inhibitors include lopinavir/ritonavir (LPV/r) 
and atazanavir (ATV).[12] The following ARV regimens were available during the study period. First 
line regimens comprised of d4T/3TC/EFV, d4T/3TC/NVP, TDF/3TC/EFV, TDF/3TC/NVP, 
FTC/TDF/EFV, FTC/TDF/NVP, AZT/3TC/EFV, AZT/3TC/NVP, ABC/3TC/EFV, ABC/3TC/NVP. 
Second line regimens consisted of TDF/3TC and LPV/r, AZT/3TC and LPV/r or ABC/3TC and LPV/r. 
 
South Africa has the largest antiretroviral (ARV) treatment rollout programme in the world, which 
achieved a 75% increase in ART services between 2009 and 2011. By the end of October 2012, over 
two million people were receiving ART, surpassing SA's universal access target (80%) in accordance 
with the 2010 WHO treatment guidelines (offering ART to people with a CD4 count less than 350 
cells/mm³).[3] Research has shown that ART increases the emotional and physical quality of life for 
people living with HIV/AIDS.[5,6] Conversely, even with ART, HIV/AIDS patients face countless 
challenges. These patients remain at risk of adverse drug reactions (ADRs) and other complications, 






A retrospective review on ADRs reported in Mpumalanga (South Africa) from 2011 to 2013 depicted 
that a total of 1756 HIV-infected individuals experienced an ADR whilst on ART.[8] During May 2007 
– May 2008, 3534 patients experienced ADRs in KwaZulu-Natal (KZN) as a result of ART, where 
stavudine was implicated as the possible causative agent in 93% of these reports.[9] Patients that are on 
ART are at increased risk of experiencing ADRs due to the effect of the disease, as well as the complex 
drug regimens that they take.[7] Numerous patients have been reported to have toxicity concerns and on 
many occasions they are indisposed to start or adhere to treatment.[10] Thus, ADRs may jeopardize the 
confidence in the safety of ART, thereby altering patient adherence, increasing the risk for the 
emergence of drug resistance, and reducing treatment efficacy.[10,11]  
 
The risk of ADRs arises due to the effect of disease on the immune system and the safety profiles of the 
multifaceted ARVs.[11] There are a range of ADRs associated with ART that have been recognized, and 
may be short to long term and/or mild to severe, depending on the environment.[11] ADRs in developing 
countries may diverge from those in developed countries because of high prevalence of conditions such 
as tuberculosis, poverty, malnutrition and patients presenting with an advanced stage of the disease.[11] 
Besides the impact of ADRs on morbidity and mortality and the direct cost of managing these events, 
ADRs also have other associated costs in terms of the loss of confidence in the healthcare system, 
economic loss to the pharmaceutical industry, non-adherence to treatment, and development of drug 
resistance.[11,12] Although it is challenging to measure these costs, it is apparent that they may constitute 
a profound impact on the resources of the healthcare system. The WHO defines pharmacovigilance 
(PV) as “the science and activities relating to the detection, assessment, understanding, and prevention 
of adverse effects or any other possible drug-related problems.”[13] The PV system safeguards the public 
through timely and efficient identification, assessment, collection, and communication of medicine-
related adverse reactions.[13] A comprehensive PV system includes both active and passive surveillance 
methods, effective mechanisms to communicate medication safety information, collaboration among a 
wide range of partners and organizations, and incorporation of PV activities into the various levels of 
the health system, from the facility to the national levels.[13] 
 
South Africa uses a spontaneous reporting system in which healthcare providers are responsible for 
reporting suspected ADRs.[9] After sufficient monitoring, laboratory tests and adherence counseling, an 
ADR report form is filled and submitted to the NDoH.[9] Although many drugs have been used and 
studied in developed countries, their safety profiles may not necessarily be applicable to other settings 
where the incidence, pattern, and severity of ADRs may differ because of local environmental and 
genetic influences.[11,12] Further, scant data on the global burden of ADRs is available.[11,13] Thus, the 





It seems clear from the available evidence that ADRs have become a major global health problem that 
needs to be addressed at all levels of healthcare.[11] The lack of awareness of the size and severity of the 
problem are partially to blame for this silent epidemic.[13] Furthermore, a large proportion of these 
ADRs can be prevented through more judicious medicine use.[14] Knowledge of the most prevalent 
ADRs, ARVs involved, and population groups at risk can help pave the way to ameliorate the incidence 
of ADRs experienced by specific populations in South Africa. 
 
This can assist with reinforcing the goals set out by the NDoH to help strengthen strategies to maximize 
patient safety, allow for easier patient monitoring, ensure the rational use of medicines, and reduce 
healthcare costs.[4] Considering the impact ADRs have on a patients quality of life, and morbidity and 
mortality rates in South Africa, a major stepping stone to achieving ways to detect or prevent ADRs 
before they proliferate would be to know which population groups are most susceptible to these harmful 
reactions and which ARVs are most likely to cause them.[4] 
 
No studies have been conducted to quantify the types of ADRs experienced most frequently by specific 
patient population groups in South Africa. In addition, this study will add to the growing literature as it 
focuses on ADR reports from 01 January 2010 up to and including 31 December 2014. It will also 
highlight the types of ADRs reported, patient demographics and ARVs involved.  
 
The aim of this study was therefore to describe the ADRs reported in South Africa with reference to the 




















The study focused on ADRs reported in South Africa to the National Department of Health. All case 
reports submitted to the NDoH over the stipulated time frame (01 January 2010 – 31 December 2014), 
were included in the study. A total of 4286 ADR reports were received, of which 1797 were excluded 
from the study as per the inclusion and exclusion criteria.  The inclusion criteria encompassed case 
reports that had an ADR reported with the use of ARVs and were submitted during 01 January 2010 – 
31 December 2014. The exclusion criteria consisted of case reports that; 1) were incomplete and had no 
ADR or ARV indicated (which could be due to incomplete data capturing/reporting), 2) had ADRs 
associated with medicines other than ARVs (e.g. anti-tuberculosis and anti-hypertensive medicines), 3) 
were ADR forms submitted for ARV treatment failure, and 4) were received out of the stipulated time 
frame. Therefore, the sample size accumulated to 2489 reports for analysis. However, for each of the 
2489 reports that were further analysed, not all information was received on the case reports for the 
following variables: 1) age, 2) gender, 3) ARV regimen and 4) patient outcome. These reports were still 
included in the study as they had an ADR and ARV reported. All of the results are based on information 
completed on the reporting forms by the healthcare providers and captured by the NDoH 
Pharmacovigilance centre – South Africa.  
 
Full ethical approval for the study was obtained from the University of KwaZulu-Natal, and permission 
to use the data was sourced from the South African National Department of Health.  
 
Sampling, data collection and analysis 
A retrospective quantitative study was carried out. Data was obtained electronically from the National 
Department of Health which is situated in Pretoria, South Africa. The data was in the form of case study 
reports captured in Microsoft Office Excel document format. Data included the type of ADR reported 
(e.g. dermatological, metabolic, etc.), the patient outcome (e.g. resulting in death, life threatening, etc.), 
the ARVs that were involved, the patient’s age, gender, weight and underlying disease, as well as their 
ARV regimen. Data was coded using numbers and thereafter transcribed onto a Microsoft Excel 
(version 2010) data extraction sheet and subsequently analysed using SPSS (version 19).  
 
Descriptive and inferential analyses were conducted. Descriptive analysis included information on 
frequencies, percentages, measures of central tendency (e.g. mean, median and mode), and measures of 
variability (e.g. range, standard deviation and variance). Inferential analysis was carried out to 




difference between variables with a p-value of less than 0.05 was considered to be statistically 
significant. Close attention was paid to the most prevalent types of ADRs, anti-retroviral medicines 
involved, and patient demographics in order to identify if some populations are more at risk of 





































Overview of patient demographics 
A total of 2489 case reports were analysed, of which the majority of ADR reports submitted were ADRs 
experienced by female patients (n=1511, 66.7%) as compared to male patients (n=755, 33.3%) (Table 
1). The mean weight of both males and females who experienced ADRs was 62.5 ± 18.51kg (n=1796) 
and almost half of the patients were in the 30-44 year age group (n=1136, 49.9%). This was followed by 
27% (n=615) of the patients in the 45-59 year age group and 12.9% (n=295) of patients aged 15-29 
years. The 0-14 and ≥60 year old patients experienced the least amount of ADRs with 5.4% (n=121) 
and 4.9% (n=112) of ADRs having occurred in these groups, respectively (Table 1). The mean age was 
39.06 ± 13.02 years old.  
 
Analysis of ADRs and associated ARVs 
The reported ADRs and their associated ARVs are described in Table 2. The 10 most commonly 
reported ADRs associated with the use of ARVs were peripheral neuropathy (n=472, 19%), 
lipodystrophy (n=471, 18.9%), serious skin reactions (n=266, 10.7%), gynaecomastia (n=219, 8.8%), 
renal failure (n=140, 5.6%), dizziness (n=133, 5.3%), hyperlactatemia (n=118, 4.7%), 
psychosis/hallucinations (n=47, 1.9%), sleep disturbances (n=44, 1.8%) and vomiting (n=44, 1.8%).  
 
Stavudine was implicated in 50.46% (n=1256) of the reports and this was followed by efavirenz 
(n=572, 22.98%), zidovudine (n=209, 8.40%), tenofovir (n=203, 8.16%), nevirapine (n=153, 6.15%) 
and abacavir (n=120, 48%) (Table 2). 
 
The total number of patients who experienced ADRs related to the use of stavudine was 1256. Of this, 
peripheral neuropathy and lipodystrophy accounted for 29.8% (n=374) and 32.4% (n=407) of the cases, 
respectively. Other common ADRs experienced by stavudine users were hyperlactatemia (n=87, 6.9%), 
gynaecomastia (n=68, 5.4%), lipoatrophy (n=23, 1.8%) and lactic acidosis (n=4, 0.3%). Skin reactions 
were mainly caused by nevirapine (n=97, 63.4%) and efavirenz (n=86, 15%). Patients being treated 
with efavirenz were more likely to experience gynaecomastia (n=131, 22.9%), as compared to 
tenofovir, that was found to mainly cause renal failure (n=100, 49.3%) (p=0.000). Tenofovir was also 
implicated in 8.9% (n=18) of the peripheral neuropathy cases as well as 8.4% (n=17) of the serious skin 
reaction reports. Zidovudine was commonly associated with ADRs like anaemia (n=49, 23.4%), 
peripheral neuropathy (n=31, 14.8%), lipodystrophy (n=25, 12%) and hyperlactatemia (n=22, 10.5%). 
Gastrointestinal disturbances, like vomiting, was commonly reported among patients who took 




responsible for 38 (1.53%) of the ADRs (Table 2). 
 
Analysis of ARVs in relation to patient demographics 
Stavudine caused statistically significant more ADRs in female patients (n=797, 52.7%) as opposed to 
male patients (n=338, 44.8%) (p=0.000). Efavirenz was also implicated with more ADRs in females 
(n=266, 17.6%) as opposed to males (n=259, 34.4%). In the 0-14 year age group, stavudine was 
responsible for the most amount of ADRs (n=97, 80.2%). In the 30-44 year age group, 49.3% (n=561) 
of patients developed ADRs associated with the use of stavudine, which was the highest occurrence for 
any ARV in any age group. Patients who were in the 15-29 (n=81, 27.5%), 30-44 (n=266, 23.4%) and 
45-59 (n=147, 23.9%) year age groups experienced ADRs mostly attributed to the use of efavirenz. 
Nevirapine was associated with ADRs that occurred more in females (n=124, 8.2%) as opposed to 
males (n=27, 3.6%). Patients who were ≥60 years old mainly experienced ADRs caused by the use of 
stavudine, efavirenz and tenofovir (Table 3). 
 
Analysis of ADRs in relation to patient demographics 
Patients aged ≥60 years old were found statistically significant more likely to experience peripheral 
neuropathy (n=21, 18.8%) as opposed to those aged 0-14 years who mainly experienced lipodystrophy 
(n=47, 38.8%) (p=0.000). Peripheral neuropathy (n=283, 18.7%) and lipodystrophy (n=342, 22.6%) 
were the two most frequently reported ADRs among female patients. Skin rash was mainly prevalent 
among female patients in the 30-44 year age group. Gynaecomastia was the most commonly reported 
ADR among male patients (n=167, 22.1%) as opposed to anaemia which was the least reported ADR in 
male patients (n=15, 2%) (Table 1). 
 
Analysis of the regimen duration prior to developing an ADR  
The regimen duration prior to ADRs indicated how long patients were on that particular regimen until 
they elicited a sign or symptom indicative of an ADR. The regimen duration prior to the manifestation 
of ADRs was measured from the ARV start date to the report date. A total of 13 ARV regimens were 
identified in the ADR reports (n=1236). Amongst these regimens, 49.7% (n = 666) of the patients were 
on ARV regimen 1 (d4T/3TC/EFV) at the time of reporting. Other regimens implicated were 
3TC/TDF/EFV (n=253, 20.5%) and 3TC/AZT/EFV (n=66, 5.3%). The mean regimen duration was 34.7 
± 27.2 months. The mode for this variable was 1 month (n=155), indicating that most patients presented 







Seriousness of the reported ADRs 
Seriousness was measured by the patients’ treatment outcome, as described in Table 4. Of the seven 
outcomes identified, majority of the patients (n=2196, 97.38%) required an intervention to prevent any 

































Table 1: ADRs reported in relation to the patient demographics  
 
 
*Gender was extracted for 2266 of the 2489 ADR case reports.  
**Age was extracted for 2280 of the 2489 ADR case reports.  
***Includes ADRs that were listed under the category “other” on the ADR form 















                                      GENDER* n (%)                           AGE GROUP (YEARS)** n (%) 
      ADR                    MALES       FEMALES       0-14           15-29             30-44             45-59           ≥60 
                                     n=755            n=1511          n=122         n=295          n=1137           n=615       n=111 
Peripheral  
Neuropathy 
135 (17.9) 283 (18.7) 15 (12.4) 40 (13.6) 205 (18.3) 157 (25.5) 21 (18.8) 
Lipodystrophy 97 (12.8) 342 (22.6) 47 (38.8) 42 (14.2) 229 (20.2) 106 (17.2) 13 (11.6) 
Skin Rash 67 (8.9) 192 (12.7) 14 (11.6) 39 (13.2) 132 (11.6) 58 (9.4) 6 (5.4) 
Gynaecomastia 167 (22.1) 44 (2.9) 6 (5) 24 (8.1) 115 (10.1) 42 (6.8) 16 (14.3) 
Renal Failure 54 (7.2) 73 (4.8) - 6 (2) 47 (4.1) 50 (8.1) 23 (20.5) 
Hyperlactatemia 27 (3.6) 58 (3.8) 7 (5.8) 18 (6.1) 51 (4.5) 25 (4.1) 4 (3.6) 
Anaemia 15 (2) 48 (3.2) - 16 (5.4) 37 (3.3) 13 (2.1) 4 (3.6) 
Other***  182 (24.1) 409 (27.1) 31 (25.6) 102 (34.6) 286 (25.2) 146 (23.7) 22 (19.6) 

















































































































Serious skin reactions 




































































































































































































































Multiple 155(6.2) 110(8.8) 30(5.2) 5(2.4) 5(2.5) 3(2) - 2(5.3) - 
Other* 207(8.3) 95(7.6) 39(6.8) 22(10.5) 23(11.3) 16(10.5) 1(8.3) 5(13.2) 6(13) 
 













Table 3: ARVs reported in relation to the patient demographics  
 
 
*Gender was extracted for 2266 of the 2489 ADR case reports. 
**Age was extracted for 2280 of the 2489 ADR case reports.  
***Includes ADRs caused by ARVs other than those listed above. 
 
Table 4: Seriousness of the reported ADRs 
 
N=2489 
Seriousness of reported ADRs*** 
n=2255 
Frequency n (%) 
Required intervention 2196 (97.38) 
Symptoms improved 37 (1.64) 
Resulted in disability 1 (0.04) 
Life-threatening 2 (0.09) 
Patient monitored 9 (0.40) 
Outcome pending 5 (0.22) 
Patient demised 5 (0.22) 
 
***Seriousness was extracted for 2255 of the 2489 ADR case reports. 
 
N=2489 
                            GENDER * n (%)                             AGE GROUP (YEARS)** n (%) 
      ARV            MALES      FEMALES       0-14           15-29            30-44             45-59           ≥60 
                              n=755         n=1511          n=122         n=295          n=1137           n=615      n=111 
Stavudine 338 (44.8) 797 (52.7) 97 (80.2) 120 (40.7) 561 (49.3) 318 (51.8) 55 (49.1) 
Efavirenz 259 (34.4) 266 (17.6) 9 (7.4) 81 (27.5) 266 (23.4) 147 (23.9) 22 (19.6) 
Nevirapine 27 (3.6) 124 (8.2) 1 (0.8) 37 (12.5) 81 (7.1) 16 (2.6) 2 (1.8) 
Zidovudine 36 (4.8) 139 (9.2) 1 (0.8) 31 (10.5) 90 (7.9) 55 (9) 11 (9.8) 
Tenofovir 63 (8.4) 126 (8.3) - 13 (4.4) 94 (8.3) 56 (9.1) 21 (18.8) 
Abacavir 5 (0.7) 6 (0.4) 7 (5.8) - 1 (0.1) 3 (0.5) - 
Multiple  16 (2.1) 20 (1.3) 2 (1.6) 6 (2) 22 (1.9) 8 (1.3) - 






The majority of ADRs were seen among female patients as opposed to male patients. In addition, this 
study had a higher number of female patients receiving ARV treatment as opposed to male patients. 
Female patients were more likely to experience peripheral neuropathy, lipodystrophy, skin rash, 
anaemia and hyperlactatemia (Table 1). Male patients were more prone to experience gynaecomastia 
and peripheral neuropathy (Table 1). The outsized difference in ADRs between males and females have 
been reported in studies conducted globally and could be due to the body structure and weight 
differences in these population groups, and hence the variance in their ability to tolerate and metabolise 
drugs.[7,15] 
 
Peripheral neuropathy and lipodystrophy (mainly attributed to female patients on stavudine treatment in 
the 30-44 year age group), skin reactions and gynaecomastia (caused mainly by efavirenz in the same 
age group) reported in this study showed that the age group of 30-44 were at specific risk to these 
ADRs. The 45-59 year age group attained the second highest total number of ADRs and this comprised 
mainly of peripheral neuropathy, lipodystrophy, skin reactions and renal failure (Table 1). According to 
Statistics South Africa most patients receiving ARV treatment in SA during 01 January 2010 – 31 
December 2014 were in the 30-44 year age group.[3] This suggests that the high incidence of ADRs 
among patients in this group could be due to the high number of patients receiving ARV treatment and 
belonging to this particular age group at the time of reporting.   
 
The 10 most commonly reported ADRs reported with the use of ARVs were peripheral neuropathy 
(n=472, 19%), lipodystrophy (n=471, 18.9%), serious skin reactions (n=266, 10.7%), gynaecomastia 
(n=219, 8.8%), renal failure (n=140, 5.6%), dizziness (n=133, 5.3%), hyperlactatemia (n=118, 4.7%), 
psychosis/hallucinations (n=47, 1.9%), sleep disturbances (n=44, 1.8%) and vomiting (n=44, 1.8%). A 
similar observation was made in other studies.[11,14] Stavudine was seen to be the ARV having the 
strongest association to most of the commonly reported ADRs as compared to other ARVs (Table 2). 
Some experts believe that this is caused by stavudine damaging the mitochondria, causing a range of 
side effects faster than most drugs in its class.[16]  
 
Patients who were initiated on tenofovir-based regimens were more likely to experience renal failure. 
The high incidence of renal failure was striking and somewhat perplexing, however a study conducted 
among ARV patients in KZN also found a large proportion of patients, treated with tenofovir, 
experiencing renal failure.[9] Females, aged 30-44 years old, who were treated with zidovudine, 




anaemia development after ART initiation with zidovudine-based regimens, specifically among female 
patients (Table 3).[15] These findings concur with studies that have found this to be due to the fact that 
females have lower haemoglobin levels than males, hormonal imbalances and menstrual cycles.[14,15]  
 
A considerably high rate of patients required an intervention to prevent any significant impairment 
and/or disability (Table 4). Patients that required an intervention (either a change in regimen or 
supplementary drug) were mostly being treated with stavudine. Patients on stavudine-containing 
regimens presented an increased incidence of ADRs within 1 month of ARV initiation.  These results 
coincide with other studies that have shown that stavudine causes ADRs quicker than any other ARV in 































In hope to endorse the rational and cost-effective use of medicines, to ensure patient safety, and to 
minimize morbidity and mortality rates, studies have been conducted in the different provinces of South 
Africa to help describe ADRs reported with reference to HIV-infected patients, ARV regimens, and 
reporting systems. However, no studies conducted have quantified the types of ADRs experienced most 
frequently by specific population groups in South Africa.  
 
This study therefore showed that there are significant ADRs associated with the use of ARVs. The 
commonest ADRs reported were peripheral neuropathy, lipodystrophy, serious skin reactions, 
gynaecomastia and renal failure. In addition, female patients, aged 30-44 years old were found to be 
more susceptible to these reactions as opposed to males in the same age group. Most reactions were 
caused due to the use of stavudine, efavirenz, zidovudine, nevirapine and tenofovir in the population 
groups identified in this study. The results of this study can therefore assist in the treatment 
individualization of patients in order to enhance adherence and improve the success of ARV therapy in 





















1. World Health Organization. World health report (statistics), Geneva: WHO, 2014. 
http://www.who.int/hiv/data/en/ (accessed 21 September 2015).  
 
2. The Joint United Nations Programme on HIV and AIDS. UNAIDS report on the global AIDS 
epidemic. Geneva: UNAIDS, 2012. 
http://www.unaids.org/en/resources/campaigns/globalreport2013/factsheet (accessed 19 September 
2015). 
 
3. AIDS Foundation of South Africa. HIV/AIDS incidence and prevalence in South Africa. Durban: 
AIDS Foundation of South Africa, 2012. 
http://www.aids.org.za/hivaids-in-south-africa/ (accessed 19 September 2015). 
 
4. The National Department of Health of South Africa. Operational Plan for Comprehensive HIV and 
AIDS Care, Management and Treatment for South Africa. Pretoria: NDoH, 2003. 
http://www.hst.org.za/publications/operational-plan-comprehensive-hiv-and-aids-care-
management-and-treatment-south-africa (accessed 17 September 2015). 
 
5. Ruud KW, Toverud EL, Radloff S, Srinivas SC. Antiretroviral treatment and follow-up of HIV-
infected patients by healthcare providers in South African public primary healthcare. J Assoc 
Nurses AIDS Care 2010;21(5):417-428. [http://doi:10.1016/j.jana.2009.12.003] [PMID: 20303798] 
 
6. Wouters E, van Loon F, van Rensburg D, Meulemans H. State of the ART: clinical efficacy and 
improved quality of life in the public antiretroviral therapy program, Free State Province, South 
Africa. AIDS Care 2009;21(11):1401-1411. [http://doi:10.1080/09540120902884034] [PMID: 
20024717] 
 
7. Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a 
South African hospital serving a community with a high HIV/AIDS prevalence: prospective 
observational study. Br J Clin Pharmacol 2008;65(3):396-406 [http://doi:10.1111/j.1365-
2125.2007.03034.x] [PMCID: PMC2291259] 
 
8. Dheda M, Distefano K, Sunduzwayo K, Williams F, Kambafwile H. Decentralized HIV/AIDS 






9. Suleman F, Manickum VK. Evaluating adverse drug reactions in KwaZulu-Natal, Afr J AIDS Res 
2012;11(2):75-81 [http://dx.doi.org/10.2989/16085906.2012.698050] 
 
10. Abdool Karim SS, Coovadia HM, Mayosi BM, et al. (2012). Health in South Africa: changes and 
challenges since 2009 The Lancet 2012;380(9858):2029-2043. [http://dx.doi.org/10.1016/S0140-
6736(12)61814-5] [PMID: 23201214] 
 
11. Pirmohamed M, Atuah KN, Dodoo ANO, Winstanley P. Pharmacovigilance in developing 
countries. BMJ 2007;335(7618):462. [http://doi:10.1136/bmj.39323.586123.BE] [PMCID: 
1971195] 
 
12. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a 
meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205 
[http://doi:10.1001/jama.279.15.1200] [PMID: 9555760] 
 
13. World Health Organization. Pharmacovigilance: Ensuring the Safe Use of Medicines – WHO 
Policy Perspectives on Medicines. Geneva: WHO, 2004. 
http://whqlibdoc.who.int/hq/2004/WHO_EDM_2004.8.pdf (accessed on 26 August 2015) 
 
14. Nagpal M, Tayal V, Kumar S, Gupta U. Adverse drug reactions to antiretroviral therapy in AIDS 
patients at a tertiary care hospital in India: A prospective observational study. Indian J Med Sci 
2010;64(6):245-252. [http://doi:10.4103/0019-5359.99597] [PMID: 22885315] 
 
15. Dube NM, Summers R, Tint KS, Mayayise G. A pharmacovigilance study of adults on highly 
active antiretroviral therapy, South Africa: 2007 – 2011. Pan Afr Med J 2012;11(39):435-442. 
[http:// doi: 10.1186/s12981-015-0044-0] [PMID: 22593775] 
 
16. Hammond E, Nolan D, McKinnon E, James I, Mallal S. Differential effects of nucleoside reverse 
transciptase inhibitor (NRTI) regimens on adipocyte mitochondrial DNA depletion in HIV-infected 










4.1 Introduction  
 
This study was carried out to describe the ADRs reported in South Africa amongst patients using 
ARVs, with reference to the types and seriousness of ADRs reported, patient demographics associated 
with specific ADRs, and the types of ARVs mostly involved in ADRs. Although many drugs have been 
used and studied in developed countries, their safety profiles may not necessarily be applicable to other 
settings where the incidence, pattern, and severity of ADRs may differ because of local environmental 
and genetic influences. Further, there is scant information available on the burden of ADRs due to the 
use of ARVs among HIV-infected people in South Africa.  
 
4.1.1 Strengths of the study methodology and design 
Data collection was cost-effective as the data sets used in the study were obtained via email (from the 
NDoH PV centre) as a Microsoft Excel document. The data was easy to analyse considering that it was 
quantitative and obtained in the form of an extraction sheet and made available electronically. This 
study comprised of a large sample size (N=2489). The study looked at case reports that were submitted 
from 01 January 2010- 31 December 2014, this allowed for a broader view of the case reports.  
 
4.2 Conclusions drawn from the study findings 
 
The aim of this study was to describe the ADRs reported in South Africa with reference to the types and 
seriousness of ADRs reported, patient demographics, and ARVs involved. To achieve this, the 
following specific objectives were outlined:  
 To identify the types of ADRs that have been reported in South Africa. 
 To identify the ARVs most involved in the reported ADRs mentioned above. 
 To determine the seriousness of reported ADRs based on the patient outcome. 
 To examine the patient demographics of the reported ADRs in relation to the type of ADR     
and ARVs implicated. 
 
   Conclusions drawn from the study findings based on each of the objectives   
 The 10 most commonly reported ADRs associated with the use of ARVs were peripheral 




10.7%), gynaecomastia (n=219, 8.8%), renal failure (n=140, 5.6%), dizziness (n=133, 5.3%), 
hyperlactatemia (n=118, 4.7%), psychosis/hallucinations (n=47, 1.9%), sleep disturbances 
(n=44, 1.8%) and vomiting (n=44, 1.8%). 
  The most commonly reported ARVs associated with ADRs were stavudine (n=1256, 50.46%) 
and efavirenz (n=572, 22.98%). Following this was zidovudine (n=209, 8.40%), tenofovir 
(n=203, 8.16%), and nevirapine (n=153, 6.15%).  
 Seriousness was measured by patient outcome. Of the seven outcomes identified, majority of 
the patients (n=2196, 97.38%) required an intervention to prevent any significant impairment or 
disability. 
 Majority of ADR reports submitted were ADRs experienced by female patients (n=1511, 
66.7%) as compared to male patients (n=755, 33.3%). Almost half of the patients were in the 
30-44 year age group (n=1136, 49.9%). Stavudine caused more ADRs in female patients 
(n=797, 52.7%) than male patients (n=338, 44.8%). Efavirenz was also responsible for more 
ADRs in female patients (n=266, 17.6%) as compared to male patients (n=259, 34.4%). 
Peripheral neuropathy (n=21, 18.8%) and renal failure (n=23, 20.5%) were reported in patients 
aged ≥60 years as compared to patients in the 0-14 year age group in which lipodystrophy 
(n=47, 38.8%)  was mostly reported.  
 
4.3 Significance of the study  
 
 Knowledge of the most prevalent ADRs, medicines involved, and population groups at risk can 
help pave the way to ameliorate the incidence of ADRs experienced by specific populations in 
South Africa. ADRs can have a detrimental effect on patient outcome, adherence, and 
management.  
 The results of this study can assist in the treatment individualization of patients in order to 
enhance adherence and improve the success of ARV therapy in South Africa.  
 This can also assist with reinforcing the goals set out by the National Department of Health to 
help strengthen strategies to maximize patient safety, allow for easier patient monitoring, ensure 
the rational use of medicines, and reduce healthcare costs.  
 Considering the impact ADRs have on a patient’s quality of life, and morbidity and mortality 
rates in South Africa, a major stepping stone to achieving ways to detect or prevent ADRs 
before they proliferate would be to know which population groups are most susceptible to these 






4.4 Limitations of the study 
 
 Underreporting – many ADR reports were incomplete. This lack of information (age, gender, ADR, 
ARV, outcome) resulted in some patients’ case reports being excluded from the study.  
 Reported ADRs were restricted to those that were serious and required a change in drug regimen, 
therefore non-serious ADRs that did not require a change in regimen were not reported and not 
included in this study.   
 The data obtained and used in this study was restricted to public-sector institutions; hence ADRs 
that could have occurred among patients from private-sector institutions were not taken into 
consideration.  
 The use of complementary and/or herbal medicines by these patients was not considered in this 
study. Only medicines that patients were receiving from their relevant public-sector institutions 
were considered. Therefore, drug interactions amongst herbal/complementary medicines with 
ARVs were not considered in terms of possibly causing the ADR or influencing its outcome.  
 
4.5 Recommendations  
 
 This study was restricted to case reports received from public-sector institutions; hence ADRs 
were not included from private-sector institutions. ADR reports from both public-sector and 
private-sector can provide a greater insight and increase the generalisability when studying 
ADRs. Therefore, further studies should incorporate both sectors.    
 Further studies on the topic should take into consideration herbal/complementary medicines 
that patients use to treat concomitant diseases and their possible drug-drug interaction(s) with 
ARVs as this could possibly influence the outcome of ADRs.  
 The importance of the completion of ADR forms should be addressed on a direct level with all 
healthcare providers, as underreporting leads to lack of vital information supplied which can 
create hurdles during data analysis.  
 
      4.6  Chapter summary    
 
The final chapter highlighted the conclusions drawn from the findings of the study, described the 
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